Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant
- PMID: 38211583
- PMCID: PMC10901529
- DOI: 10.1016/j.chom.2023.12.003
Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant
Abstract
Ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has given rise to recombinant Omicron lineages that dominate globally (XBB.1), as well as the emergence of hypermutated variants (BA.2.86). In this context, durable and cross-reactive T cell immune memory is critical for continued protection against severe COVID-19. We examined T cell responses to SARS-CoV-2 approximately 1.5 years since Omicron first emerged. We describe sustained CD4+ and CD8+ spike-specific T cell memory responses in healthcare workers in South Africa (n = 39) who were vaccinated and experienced at least one SARS-CoV-2 infection. Spike-specific T cells are highly cross-reactive with all Omicron variants tested, including BA.2.86. Abundant nucleocapsid and membrane-specific T cells are detectable in most participants. The bulk of SARS-CoV-2-specific T cell responses have an early-differentiated phenotype, explaining their persistent nature. Overall, hybrid immunity leads to the accumulation of spike and non-spike T cells evident 3.5 years after the start of the pandemic, with preserved recognition of highly mutated SARS-CoV-2 variants.
Keywords: BA.2.86 sub-lineage; SARS-CoV-2; T cell response; T cell sustainability; cross-reactivity.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.S. is a consultant for AstraZeneca Pharmaceuticals, Calyptus Pharmaceuticals Inc, Darwin Health, EmerVax, EUROIMMUN, F. Hoffman-La Roche Ltd, Fortress Biotech, Gilead Sciences, Granite bio., Gritstone Oncology, Guggenheim Securities, Moderna, Pfizer, RiverVest Venture Partners, and Turnstone Biologics. A.G. is a consultant for Pfizer. L.J.I. has filed for patent protection for various aspects of T cell epitope and vaccine design work.
Figures



Similar articles
-
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant.Cell Host Microbe. 2024 Feb 14;32(2):156-161.e3. doi: 10.1016/j.chom.2023.12.010. Epub 2024 Jan 10. Cell Host Microbe. 2024. PMID: 38211584
-
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity.Cell Rep. 2023 Aug 29;42(8):112888. doi: 10.1016/j.celrep.2023.112888. Epub 2023 Jul 31. Cell Rep. 2023. PMID: 37527039
-
SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals.Viruses. 2022 Dec 29;15(1):101. doi: 10.3390/v15010101. Viruses. 2022. PMID: 36680141 Free PMC article.
-
The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron.Viruses. 2022 Sep 10;14(9):2009. doi: 10.3390/v14092009. Viruses. 2022. PMID: 36146815 Free PMC article. Review.
-
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.Front Immunol. 2023 May 23;14:1130539. doi: 10.3389/fimmu.2023.1130539. eCollection 2023. Front Immunol. 2023. PMID: 37287979 Free PMC article. Review.
Cited by
-
Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1.Viruses. 2024 Mar 20;16(3):473. doi: 10.3390/v16030473. Viruses. 2024. PMID: 38543838 Free PMC article.
-
Predicting SARS-CoV-2-specific CD4+ and CD8+ T-cell responses elicited by inactivated vaccines in healthy adults using machine learning models.Clin Exp Med. 2025 Jul 8;25(1):236. doi: 10.1007/s10238-025-01772-2. Clin Exp Med. 2025. PMID: 40627199 Free PMC article.
-
Structural basis of a human antibody targeting SARS-CoV-2 nucleocapsid protein dimerization domain and interfering with RNA-binding.Commun Biol. 2025 Aug 19;8(1):1248. doi: 10.1038/s42003-025-08648-x. Commun Biol. 2025. PMID: 40830575 Free PMC article.
-
Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.Front Immunol. 2024 Sep 5;15:1432348. doi: 10.3389/fimmu.2024.1432348. eCollection 2024. Front Immunol. 2024. PMID: 39301017 Free PMC article.
-
T Cell Responses to BA.2.86 and JN.1 SARS-CoV-2 Variants in Elderly Subjects.Vaccines (Basel). 2024 Dec 23;12(12):1451. doi: 10.3390/vaccines12121451. Vaccines (Basel). 2024. PMID: 39772110 Free PMC article.
References
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous